Hear from the experts about new treatment strategies in adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), including appropriate use of tyrosine kinase inhibitors, how BCR-ABL mutation influences treatment decisions, and how patient fitness informs therapy selection. Clinical scenarios allow you to compare your treatment decisions with the experts and will provide insight into treatment for your patients with Ph+ ALL.
0.25 AMA PRA Category 1 Credit™
Jan 29, 2018
Jan 29, 2019
Daniel DeAngelo, MD, PhDDana-Farber Cancer Institute
Boston, Massachusetts, United States
Elias Jabbour, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
- Induction therapy regimens in Ph+ ALL
- Relapsed and refractory Ph+ ALL
- Treatment of fit vs unfit patients
This activity is intended for hematologists, medical oncologists, and other healthcare professionals involved in the treatment of patients with acute lymphoblastic leukemia.
After completion of this educational activity, participants should be able to:
- Identify risk factors for relapse in Ph+ ALL, including cytogenetic abnormalities and failure to achieve complete molecular remission
- Interpret findings from contemporary techniques like qRT-PCR and deep sequencing to better predict outcomes and adjust therapy for patients with Ph+ ALL
- Select an appropriate therapeutic approach for Ph+ ALL, taking into consideration patient fitness, diagnostic findings, and factors related to hematopoietic stem cell transplantation
This educational activity is supported by a grant from Takeda Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr DeAngelo has disclosed that he has received consulting fees from Amgen, Incyte, Novartis Oncology, Pfizer, Shire, and Takeda Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Jabbour has disclosed that he has performed contracted research for Amgen, Novartis Oncology, Pfizer, and Takeda Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.